Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis
R Messina, EM Huessler, F Puledda… - …, 2023 - journals.sagepub.com
Background Direct comparisons of the tolerability and safety of migraine preventive
treatments targeting the calcitonin gene-related peptide pathway are lacking. This study …
treatments targeting the calcitonin gene-related peptide pathway are lacking. This study …
Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.
R Messina, EM Huessler, F Puledda… - … Journal of Headache, 2023 - europepmc.org
Background Direct comparisons of the tolerability and safety of migraine preventive
treatments targeting the calcitonin gene-related peptide pathway are lacking. This study …
treatments targeting the calcitonin gene-related peptide pathway are lacking. This study …
Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.
R Messina, EM Huessler, F Puledda… - …, 2023 - search.ebscohost.com
Background: Direct comparisons of the tolerability and safety of migraine preventive
treatments targeting the calcitonin gene-related peptide pathway are lacking. This study …
treatments targeting the calcitonin gene-related peptide pathway are lacking. This study …
Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis
R Messina, EM Huessler, F Puledda… - Cephalalgia: an …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Direct comparisons of the tolerability and safety of migraine preventive
treatments targeting the calcitonin gene-related peptide pathway are lacking. This study …
treatments targeting the calcitonin gene-related peptide pathway are lacking. This study …